author-photo

Lorenza Landi

Academy for Urban School Leadership

16

Papers

287

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
Crizotinib in ROS1 and MET Deregulated NSCLC-Response.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Immune-related adverse events of pembrolizumab in a large real-world cohort of NSCLC patients with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes.

2020 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (29)
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (26)
1489PDSecondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
ROS1-rearranged non-small cell lung cancer is associated with high rate of venous thromboembolism: analysis from a phase II, prospective, multicentre, two-arms trial (METROS)

2019 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (30)
1595TiPNivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (66)
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

2019 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (46)